API.AU · Australian Pharmaceutical Industries Limited

-

Please sign in to comment on API.AU

1 Comment

Admin

4 years, 1 month ago

Australian Pharmaceutical Industries Limited is currently in a long term downtrend where the price is trading 3.9% below its 200 day moving average.

From a valuation standpoint, the stock is 99.9% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.2.

Australian Pharmaceutical Industries Limited's total revenue sank by 2.3% to $2B since the same quarter in the previous year.

Its net income has dropped by 197.7% to $-30M since the same quarter in the previous year.

Finally, its free cash flow grew by 277.2% to $43M since the same quarter in the previous year.

Based on the above factors, Australian Pharmaceutical Industries Limited gets an overall score of 2/5.

Sector	Healthcare
Industry	Medical Distribution
Exchange	AU
CurrencyCode	AUD
ISIN	AU000000API4

Beta	0.18
Market Cap	754M
PE Ratio	510.0
Target Price	1.53
Dividend Yield	2.3%

ABOUT

Australian Pharmaceutical Industries Limited

Australian Pharmaceutical Industries Limited engages in the wholesale distribution and retail of pharmaceutical, medical, health, beauty, and lifestyle products to pharmacies primarily in Australia, New Zealand, and Asian markets. It offers health and beauty products through a network of Priceline and Priceline Pharmacy franchise stores, company-owned Priceline stores, and Clear Skincare network of clinics. The company also provides non-invasive aesthetic beauty services. Australian Pharmaceutical Industries Limited was incorporated in 1910 and is based in Camberwell, Australia. As of March 31, 2022, Australian Pharmaceutical Industries Limited operates as a subsidiary of WFM Investments Pty Ltd.

API.AU · Australian Pharmaceutical Industries Limited

-

Australian Pharmaceutical Industries Limited

Earnings

Valuation

Cash Flow

Profitability

Performance

Backtest Australian Pharmaceutical Industries Limited using a moving average strategy